A changing immune profile is not equivalent to meeting a prespecified final endpoint. This distinction is particularly important when a small study reports numerous laboratory measurements. Primary study
What was reported
Twenty virally suppressed people with incomplete immune recovery received thymosin alpha-1 while continuing antiretroviral therapy; 17 completed the protocol. This was a single-arm, 24-week study. Some T-cell subsets changed, but CD4 count and the CD4/CD8 ratio did not significantly improve at week 24 versus baseline. Potentially treatment-related adverse events were reported, despite no severe drug-related events being observed. Primary report
Our appraisal: composition, count, and timing are different questions
A percentage can increase even when the corresponding absolute count does not show the same pattern. Researchers studying immune populations therefore need to preserve both the numerator and the denominator. Calling all favorable percentage changes “immune restoration” can overstate what was measured.
Repeated observations create another distinction. An overall test across visits may identify change somewhere in the series without establishing improvement at the designated final visit. An endpoint summary should not replace the final comparison with whichever earlier observation looks strongest.
The lack of a concurrent control group limits causal interpretation. Continued background therapy, variation over time, and measurement fluctuations cannot be fully separated from the added intervention. Within-person follow-up is useful, but it does not supply the missing counterfactual by itself.
Completion and tolerability should be described just as carefully. A small, selected group followed for months cannot rule out uncommon or delayed adverse effects. “No severe drug-related events observed” is narrower than “no adverse events.”
This study supports further investigation of particular immune measures. It does not establish a cure, replacement for antiretroviral therapy, or proven reduction in clinical illness.
Frequently asked questions
Was there a concurrent control arm?
No.
Did participants continue antiretroviral therapy?
Yes.
How many completed the protocol?
17 of 20 enrolled participants.
Did the final CD4 count improve significantly?
Not versus baseline at week 24.
Did some immune subsets change?
Yes.
Were all adverse events absent?
No.
Does this demonstrate an HIV cure?
No.